XML 98 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
FAIR VALUE DISCLOSURES - Additional information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 31, 2019
USD ($)
Jun. 30, 2019
USD ($)
item
Mar. 31, 2019
USD ($)
item
Jan. 31, 2019
USD ($)
May 31, 2018
USD ($)
Apr. 30, 2018
USD ($)
item
Dec. 31, 2017
USD ($)
Feb. 28, 2017
USD ($)
Dec. 31, 2019
USD ($)
Mar. 31, 2018
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Feb. 28, 2019
USD ($)
Dec. 27, 2018
USD ($)
Payments to Acquire Intangible Assets                     $ 20,914,000 $ 5,169,000 $ 97,624,000      
Goodwill, Impairment Loss                     0 0        
Finite-Lived Intangible Assets, Gross                 $ 307,225,000   $ 307,225,000 288,215,000        
Finite-Lived Intangible Asset, Useful Life                     10 years          
Inventory, Raw Materials, Gross                 34,881,000   $ 34,881,000 27,671,000        
Intangible asset impairment charge                     $ 75,000 0 903,000      
Fair Values Inputs Discount Rate                     15.00%          
Research and Development in Process                     $ 2,324,000 1,335,000 0      
Inventory, Finished Goods, Gross                 16,750,000   16,750,000 10,620,000        
Appco Pharma, LLC [Member]                                
Payments to Acquire Intangible Assets $ 80,000                              
Finite-Lived Intangible Assets, Gross 80,000                              
Finite-Lived Intangible Asset, Useful Life                   8 years            
Intangible asset impairment charge                 75,000   $ 75,000          
Pharmaceutics International, Inc and BAS ANDA LLC [Member]                                
Payments to Acquire Intangible Assets                 500,000              
Finite-Lived Intangible Asset, Useful Life                     10 years          
Senior Secured Credit Facility [Member] | Delayed Draw Term Loan [Member]                                
Long-term Debt, Gross                 118,000,000   $ 118,000,000          
Interest rate swap [Member] | Delayed Draw Term Loan [Member]                                
Derivative Asset, Notional Amount                 118,000,000   118,000,000       $ 118,000,000  
Interest Rate Derivative Liabilities, at Fair Value                 3,800,000   3,800,000          
Inderal XL [Member]                                
Payments to Acquire Intangible Assets               $ 20,200,000                
Finite-Lived Intangible Assets, Gross               $ 15,100,000                
Finite-Lived Intangible Asset, Useful Life               10 years                
Acquisition Costs Capitalized               $ 40,000                
Fair Values Inputs Discount Rate               10.00%                
Inventory, Finished Goods, Gross               $ 5,000,000                
InnoPran XL [Member]                                
Payments to Acquire Intangible Assets               30,600,000                
Finite-Lived Intangible Assets, Gross               $ 19,000,000                
Finite-Lived Intangible Asset, Useful Life               10 years                
Acquisition Costs Capitalized               $ 100,000                
Fair Values Inputs Discount Rate               10.00%                
Inventory, Finished Goods, Gross               $ 11,600,000                
IDT Australia Limited [Member] | Abbreviated New Drug Applications [Member]                                
Number Of Generic Drug Products Acquired | item           23                    
IDT Australia Limited [Member] | Abbreviated New Drug Applications [Member] | Maximum | Measurement Input, Discount Rate [Member]                                
Fair Values Inputs Discount Rate           15.00%                    
IDT Australia Limited [Member] | Abbreviated New Drug Applications [Member] | Minimum | Measurement Input, Discount Rate [Member]                                
Fair Values Inputs Discount Rate           10.00%                    
IDT Australia Limited [Member] | Acquired New Drug Applications [Member]                                
Payments to Acquire Intangible Assets           $ 2,700,000                    
Finite-Lived Intangible Assets, Gross           $ 2,500,000                    
Finite-Lived Intangible Asset, Useful Life           10 years                    
Acquisition Costs Capitalized           $ 18,000                    
Inventory, Raw Materials, Gross           200,000                    
Impax Laboratories, Inc. [Member] | Equipment [Member]                                
Finite-Lived Intangible Assets, Gross         $ 58,000                      
Finite-Lived Intangible Asset, Useful Life         5 years                      
Impax Laboratories, Inc. [Member] | Abbreviated New Drug Applications [Member]                                
Payments to Acquire Intangible Assets         $ 2,300,000                      
Finite-Lived Intangible Assets, Gross         $ 1,000,000                      
Finite-Lived Intangible Asset, Useful Life         10 years                      
Acquisition Costs Capitalized         $ 100,000                      
Contingent Consideration In An Asset Purchase         $ 10,000,000                      
Impax Laboratories, Inc. [Member] | Abbreviated New Drug Applications [Member] | Maximum | Measurement Input, Discount Rate [Member]                                
Fair Values Inputs Discount Rate         15.00%                      
Impax Laboratories, Inc. [Member] | Abbreviated New Drug Applications [Member] | Minimum | Measurement Input, Discount Rate [Member]                                
Fair Values Inputs Discount Rate         10.00%                      
Term Loan [Member] | Senior Secured Credit Facility [Member]                                
Derivative Asset, Notional Amount                 69,500,000   69,500,000 72,200,000        
Long-term Debt, Gross                 69,500,000   69,500,000 72,200,000        
Term Loan [Member] | Interest rate swap [Member]                                
Derivative Asset, Notional Amount                 69,500,000   69,500,000         $ 72,200,000
Interest Rate Derivative Liabilities, at Fair Value                 2,400,000   2,400,000          
Acquired ANDA intangible assets [Member]                                
Finite-Lived Intangible Assets, Gross                 64,704,000   $ 64,704,000 46,194,000        
Finite-Lived Intangible Asset, Useful Life                     10 years          
Acquired ANDA intangible assets [Member] | IDT Australia Limited [Member]                                
Payments to Acquire Intangible Assets           2,700,000                    
Finite-Lived Intangible Assets, Gross           $ 2,500,000                    
Finite-Lived Intangible Asset, Useful Life           10 years                    
Acquisition Costs Capitalized           $ 18,000                    
In Process Research and Development [Member] | Impax Laboratories, Inc. [Member]                                
Research and Development in Process         $ 1,300,000                      
In Process Research and Development [Member] | Impax Laboratories, Inc. [Member] | Measurement Input, Discount Rate [Member]                                
Fair Values Inputs Discount Rate         75.00%                      
Drug Applications and Marketing and Distribution Rights [Member] | New Drug Applications [Member]                                
Finite-Lived Intangible Assets, Gross                 10,900,000   $ 10,900,000          
Intangible asset impairment charge                     75,000 0 900,000 $ 6,700,000    
Marketing and distribution rights                                
Finite-Lived Intangible Assets, Gross                 10,923,000   $ 10,923,000 $ 10,423,000        
Finite-Lived Intangible Asset, Useful Life                     4 years 8 months 12 days          
Marketing and distribution rights | Appco Pharma, LLC [Member]                                
Payments to Acquire Intangible Assets 80,000                              
Finite-Lived Intangible Assets, Gross $ 80,000                              
Intangible asset impairment charge                 75,000              
Marketing and distribution rights | Pharmaceutics International, Inc and BAS ANDA LLC [Member]                                
Payments to Acquire Intangible Assets                 $ 500,000              
Finite-Lived Intangible Asset, Useful Life                     10 years          
Teva Pharmaceuticals [Member]                                
Payments to Acquire Intangible Assets       $ 16,000,000                        
Fair Values Inputs Discount Rate       12.00%                        
Cumulative Amortization Expense       $ 6,800,000                        
Additional Net Carrying Value Added To Finite Lived Intangible Assets Acquired       $ 9,200,000                        
Teva Pharmaceuticals [Member] | Impax Laboratories, Inc. [Member] | Milestone One [Member]                                
Contingent Liability Not Recognized         $ 25,000,000                      
Teva Pharmaceuticals [Member] | Impax Laboratories, Inc. [Member] | Milestone Two [Member]                                
Contingent Liability Not Recognized         $ 15,000,000                      
Teva Pharmaceuticals [Member] | Acquired ANDA intangible assets [Member]                                
Number Of Generic Drug Products Acquired | item     35                          
Finite-Lived Intangible Assets, Gross     $ 2,500,000                          
Finite-Lived Intangible Asset, Useful Life     10 years                          
Acquisition Costs Capitalized     $ 10,000                          
Fair Values Inputs Discount Rate     15.00%                          
AstraZeneca AB and AstraZeneca UK Limited [Member] | New Drug Applications [Member]                                
Payments to Acquire Intangible Assets             $ 46,500,000                  
Finite-Lived Intangible Assets, Gross             $ 46,700,000           46,700,000      
Finite-Lived Intangible Asset, Useful Life             10 years                  
Acquisition Costs Capitalized             $ 200,000                  
Contingent Consideration In An Asset Purchase             $ 3,000,000           $ 3,000,000      
Fair Values Inputs Discount Rate             10.00%                  
Coeptis Pharmaceuticals, Inc. [Member]                                
Number Of Generic Drug Products Acquired | item   7                            
Contingent Consideration In An Asset Purchase   $ 12,000,000                            
Research and Development in Process   2,300,000                            
Acquisition Costs Expensed   $ 24,000